Tapewire

Nasdaq · USD

FATE

FATE THERAPEUTICS INC

Export transactions ↓
Tapewire entity
5968
SEC CIK
0001434316
Parsed reports
323

Last 12 months

Inside the activity.

0 purchase rows · 6 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202602
Feb 202600
Mar 202600
Apr 202600
May 202602
Jun 202600
Jul 202600
Aug 202602
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
April 22, 2021 Filed Apr 26, 2021 20:03 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionCommon stock 30,000 $2.73 $81,900.00
Disclosure

SEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 1

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 423,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

Read SEC document
April 16, 2021 Filed Apr 20, 2021 16:00 UTC
Chu Yu-WayeSenior VP Clinical Development
SaleCommon stock 1,500 $84.41 $126,615.00
Disclosure

SEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 3

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,800

F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.635 to $84.61 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 16, 2021 Filed Apr 20, 2021 16:00 UTC
Chu Yu-WayeSenior VP Clinical Development
SaleCommon stock 900 $82.91 $74,619.00
Disclosure

SEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 2

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,300

F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.6175 to $83.23 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 16, 2021 Filed Apr 20, 2021 16:00 UTC
Chu Yu-WayeSenior VP Clinical Development
SaleCommon stock 875 $81.80 $71,575.00
Disclosure

SEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 1

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,200

F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.395 to $82.205 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
Exercise / conversionStock Option Right to Buy · Derivative 1,851 $0.00 Strike: $7.87 $0.00
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · derivative · entry 12

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,458

Underlying: Common Stock · 1,851 shares

Expires 2023-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F11 · derivative.exercise_date: 1/2 of the shares subject to this option vested in 48 equal monthly installments beginning on November 4, 2013. The remaining 1/2 of the shares are divided into five equal parts, and 1/5 of such remaining shares vested in 24 equal monthly installments following the Issuer's achievement of one of the five specified performance based milestones.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
Exercise / conversionStock Option (Right to Buy) · Derivative 28,149 $0.00 Strike: $2.90 $0.00
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · derivative · entry 11

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,149 shares

Expires 2026-01-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F10 · derivative.exercise_date: The shares subject to this option vested in 48 equal monthly installments beginning on February 8, 2016.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 400 $87.45 $34,979.00
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 10

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,048

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F9 · price: Represents the weighted average sale price of the shares sold ranging from $87.36 to $87.53 per share.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 5,299 $86.76 $459,732.76
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 9

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,448

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F8 · price: Represents the weighted average sale price of the shares sold ranging from $86.34 to $87.32 per share.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 4,835 $85.98 $415,732.64
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 8

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,747

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F7 · price: Represents the weighted average sale price of the shares sold ranging from $85.34 to $86.33 per share.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 2,200 $84.48 $185,865.02
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 7

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,582

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F6 · price: Represents the weighted average sale price of the shares sold ranging from $84.08 to $84.97 per share.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 3,490 $83.40 $291,080.31
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 6

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,782

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F5 · price: Represents the weighted average sale price of the shares sold ranging from $83.08 to $84.06 per share.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 4,556 $82.69 $376,714.23
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 5

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,272

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F4 · price: Represents the weighted average sale price of the shares sold ranging from $82.08 to $83.07 per share.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 8,220 $81.48 $669,731.08
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 4

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,828

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $81.02 to $81.85 per share.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
SaleCommon Stock 1,000 $80.49 $80,494.00
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 3

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,048

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $80.02 to $81.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 9.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
Exercise / conversionCommon Stock 1,851 $7.87 $14,567.37
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 2

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,048

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 22:03 UTC
TAHL CINDYSee Remarks
Exercise / conversionCommon Stock 28,149 $2.90 $81,632.10
Disclosure

SEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 1

TAHL CINDY · CIK 0001655472 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,197

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:05 UTC
Valamehr BahramChief Development Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.90 $0.00
Disclosure

SEC source: 0000899243-21-011920 · doc4.xml · derivative · entry 7

Valamehr Bahram · CIK 0001748177 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,156

Underlying: Common Stock · 25,000 shares

Expires 2026-01-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F7 · derivative.exercise_date: This option is fully vested.

Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:05 UTC
Valamehr BahramChief Development Officer
SaleCommon Stock 1,018 $94.59 $96,297.10
Disclosure

SEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 6

Valamehr Bahram · CIK 0001748177 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,740

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F6 · price: Represents the weighted average sale price of the shares sold from $94.40 to $94.90 per share.

Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:05 UTC
Valamehr BahramChief Development Officer
SaleCommon Stock 3,205 $93.75 $300,460.74
Disclosure

SEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 5

Valamehr Bahram · CIK 0001748177 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,758

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F5 · price: Represents the weighted average sale price of the shares sold from $93.31 to $94.29 per share.

Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:05 UTC
Valamehr BahramChief Development Officer
SaleCommon Stock 8,404 $92.64 $778,577.65
Disclosure

SEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 4

Valamehr Bahram · CIK 0001748177 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,963

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F4 · price: Represents the weighted average sale price of the shares sold from $92.31 to $93.27 per share.

Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:05 UTC
Valamehr BahramChief Development Officer
SaleCommon Stock 8,416 $91.94 $773,782.19
Disclosure

SEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 3

Valamehr Bahram · CIK 0001748177 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,367

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F3 · price: Represents the weighted average sale price of the shares sold from $91.30 to $92.29 per share.

Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:05 UTC
Valamehr BahramChief Development Officer
SaleCommon Stock 3,957 $90.89 $359,654.50
Disclosure

SEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 2

Valamehr Bahram · CIK 0001748177 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,783

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F2 · price: Represents the weighted average sale price of the shares sold from $90.30 to $91.29 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.

Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:05 UTC
Valamehr BahramChief Development Officer
Exercise / conversionCommon Stock 25,000 $2.90 $72,500.00
Disclosure

SEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 1

Valamehr Bahram · CIK 0001748177 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 800 $86.70 $69,360.00
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 8

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,020

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 2,900 $85.50 $247,956.09
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 7

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,820

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F8 · price: Represents the weighted average sale price of the shares sold ranging from $84.99 to $85.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 2,728 $84.20 $229,704.69
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 6

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,720

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F7 · price: Represents the weighted average sale price of the shares sold ranging from $83.775 to $84.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 2,480 $83.46 $206,989.48
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 5

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,448

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F6 · price: Represents the weighted average sale price of the shares sold ranging from $82.74 to $83.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 2,993 $81.60 $244,224.31
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 4

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,928

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F5 · price: Represents the weighted average sale price of the shares sold ranging from $81.19 to $82.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 5,174 $80.73 $417,722.37
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 3

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,921

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F4 · price: Represents the weighted average sale price of the shares sold ranging from $80.12 to $81.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 4,627 $79.58 $368,235.63
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 2

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,095

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $79.09 to $80.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
March 08, 2021 Filed Mar 9, 2021 21:02 UTC
Shoemaker Daniel DChief Scientific Officer
SaleCommon stock 3,298 $78.60 $259,235.66
Disclosure

SEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 1

Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,722

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $78.08 to $79.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:07 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionStock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $6.62 Not disclosed
Disclosure

SEC source: 0001209191-21-012326 · doc4.xml · derivative · entry 7

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 20,000 shares

Expires 2024-01-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F8 · price: Not applicable.

F7 · derivative.exercise_date: This option is fully vested.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:07 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 5,547 $103.16 $572,205.78
Disclosure

SEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 6

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,793

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F6 · price: Represents the weighted average sale price of the shares sold ranging from $102.86 to $103.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:07 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 8,602 $102.26 $879,661.16
Disclosure

SEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 5

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,340

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F5 · price: Represents the weighted average sale price of the shares sold ranging from $101.85 to $102.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:07 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 2,602 $101.42 $263,883.39
Disclosure

SEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 4

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 407,942

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F4 · price: Represents the weighted average sale price of the shares sold ranging from $100.83 to $101.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:07 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 1,848 $100.48 $185,690.92
Disclosure

SEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 3

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 410,544

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $99.825 to $100.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:07 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 1,401 $99.08 $138,816.96
Disclosure

SEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 2

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,392

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $98.65 to $99.645 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:07 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionCommon stock 20,000 $6.62 $132,400.00
Disclosure

SEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 1

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 413,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionStock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $6.62 Not disclosed
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 20

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,846

Underlying: Common Stock · 20,000 shares

Expires 2024-01-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F16 · price: Not applicable.

F17 · derivative.exercise_date: This option is fully vested.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionStock Option (right to buy) · Derivative 10,000 Not disclosed Strike: $2.73 Not disclosed
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 19

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 10,000 shares

Expires 2027-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F16 · price: Not applicable.

F17 · derivative.exercise_date: This option is fully vested.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 3,075 $100.01 $307,544.90
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 16

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,793

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F14 · price: Represents the weighted average sale price of the shares sold ranging from $99.81 to $100.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 6,520 $99.35 $647,732.01
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 15

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,868

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F13 · price: Represents the weighted average sale price of the shares sold ranging from $98.80 to $99.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 7,638 $98.45 $751,951.93
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 14

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,388

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F12 · price: Represents the weighted average sale price of the shares sold ranging from $97.80 to $98.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 12,767 $97.23 $1,241,382.65
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 13

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,026

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F11 · price: Represents the weighted average sale price of the shares sold ranging from $96.77 to $97.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionCommon stock 20,000 $6.62 $132,400.00
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 12

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 423,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

Read SEC document
January 22, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionCommon stock 10,000 $2.73 $27,300.00
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 11

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

Read SEC document
January 21, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
Exercise / conversionStock Option (right to buy) · Derivative 30,000 Not disclosed Strike: $2.73 Not disclosed
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 18

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 30,000 shares

Expires 2027-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F16 · price: Not applicable.

F17 · derivative.exercise_date: This option is fully vested.

Read SEC document
January 21, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 200 $106.96 $21,391.00
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 10

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,793

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F10 · price: Represents the weighted average sale price of the shares sold ranging from $106.84 to $107.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
January 21, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 645 $106.03 $68,391.80
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 9

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,993

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F9 · price: Represents the weighted average sale price of the shares sold ranging from $105.75 to $106.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document
January 21, 2021 Filed Jan 22, 2021 23:23 UTC
Wolchko J ScottDirector · President and CEO
SaleCommon stock 4,271 $105.25 $449,516.77
Disclosure

SEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 8

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,638

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.

F8 · price: Represents the weighted average sale price of the shares sold ranging from $104.75 to $105.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.